Skip to main content
TipRanks
Go Ultimate75% OFF

Vivoryon Therapeutics AG (0R3M) Share Price & Analysis

2 Followers

0R3M Stock Chart & Stats

€0.73-€0.01(-1.88%)
At close: 4:30 PM GMT
€0.6€0.8€1Aug 24Sep 7Sep 21Oct 5Oct 19Nov 2Nov 16
Day’s Range
EUR 0.72 - EUR 0.74
52-Week Range
EUR 0.55 - EUR 1.65
Previous Close
EUR 0.74
Volume
N/A
Average Volume (3M)
1,125
Market Cap
EUR 21.62M
Enterprise Value
EUR 29.61M
Total Cash (Recent Filing)
EUR 2.45M
Total Debt (Recent Filing)
EUR 76.00K
Price to Earnings (P/E)
―
Beta
0.57
Next Earnings
Apr 29, 2027 (Est.)
EPS Estimate
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Low Leverage

Very low leverage limits fixed financial obligations and reduces the balance-sheet burden from debt. This provides more flexibility than a highly indebted structure, although the benefit is tempered by the company’s declining equity base and continuing cash needs.

Improved Loss And Cash Burn

The substantial reduction in reported net loss and operating cash burn during 2025 indicates some improvement in financial performance. If maintained, this could extend the company’s operating runway, though cash generation remains negative and the business is not yet self-funding.

Platform-Based Drug Discovery

A defined enzyme-targeting platform and neuroscience pipeline give Vivoryon a focused basis for developing multiple small-molecule medicines. Concentration on diseases with high unmet need may support long-term opportunity if the platform produces clinically viable candidates.

Bears Say

No Recent Revenue And Persistent Losses

The absence of reported revenue in 2024–2025, together with negative gross profit and continuing operating losses, shows that the business has not yet established commercial earnings power. This leaves future financial sustainability dependent on successful development and eventual monetization.

Negative Cash Generation

Persistent negative operating and free cash flow means current activities do not fund the company’s operations. Continued cash consumption can require external financing or further balance-sheet contraction, creating an ongoing constraint on development spending and strategic flexibility.

Shrinking Equity And Asset Base

The sharp contraction in equity and total assets indicates that prior cash consumption has materially reduced financial resources. A smaller asset base provides less protection against further losses and leaves less flexibility to sustain development or absorb operating setbacks.

Vivoryon Therapeutics AG News

0R3M FAQ

What was Vivoryon Therapeutics AG’s price range in the past 12 months?
Vivoryon Therapeutics AG lowest share price was €0.55 and its highest was €1.65 in the past 12 months.
What is Vivoryon Therapeutics AG’s market cap?
Vivoryon Therapeutics AG’s market cap is €21.62M.
When is Vivoryon Therapeutics AG’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Vivoryon Therapeutics AG’s earnings last quarter?
Vivoryon Therapeutics AG released its earnings results on Aug 06, 2026. The company reported -€0.114 earnings per share for the quarter.
Is Vivoryon Therapeutics AG overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Vivoryon Therapeutics AG pay dividends?
Vivoryon Therapeutics AG pays a dividend of €0.285 which represents an annual dividend yield of ―. See more information on Vivoryon Therapeutics AG dividends here
What is Vivoryon Therapeutics AG’s EPS estimate?
Vivoryon Therapeutics AG’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Vivoryon Therapeutics AG have?
Vivoryon Therapeutics AG has 29,614,338 shares outstanding.
What happened to Vivoryon Therapeutics AG’s price movement after its last earnings report?
Vivoryon Therapeutics AG reported an EPS of -€0.114 in its last earnings report. Following the earnings report the stock price went down -28.75%.
Which hedge fund is a major shareholder of Vivoryon Therapeutics AG?
Currently, no hedge funds are holding shares in GB:0R3M
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology